Next Article in Journal
Correlation Between A Disintegrin and Metalloproteinase (ADAM) Family Proteins (8, 10, 17, 22) and Link with Neuroplasticity in Autism Spectrum Disorder
Previous Article in Journal
A Comprehensive Comparative Analysis and Phylogenetic Investigation of the Chloroplast Genome Sequences in Four Astragalus Species
Previous Article in Special Issue
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CIMB
Volume 47
Issue 12
10.3390/cimb47120979
cimb-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Curr. Issues Mol. Biol. 2025, 47(3), 154.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Knezović et al. Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr. Issues Mol. Biol. 2025, 47, 154

by
Elizabeta Knezović
1,2,†,
Marija Hefer
1,†,
Suzana Blažanović
1,
Ana Petrović
1,
Vice Tomičić
1,
Nika Srb
1,
Damir Kirner
1,
Robert Smolić
1 and
Martina Smolić
1,*
1
Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia
2
Clinical Institute of Translational Medicine, University Hospital Osijek, 31000 Osijek, Croatia
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Curr. Issues Mol. Biol. 2025, 47(12), 979; https://doi.org/10.3390/cimb47120979
Submission received: 14 November 2025 / Accepted: 19 November 2025 / Published: 25 November 2025
(This article belongs to the Special Issue The Role of the Immune System in the Progression of Chronic Liver Disease)
Versions Notes
There was an error in the original publication [1], A sentence was accidentally written in a way that it could possibly imply that resmetirom has been tested on children:
“In addition to adult MASH patients, resmetirom has shown potential for treating MASLD in children with obesity, with encouraging results in improving steatohepatitis and fibrosis in up to 36% and 27% of patients, respectively [49].”
A correction has been made to Paragraph 4 of the Section 2.4. Comprehensive Phase 3 Trials:
“In addition to adult MASH patients, resmetirom could show potential for treating MASLD in children with obesity, with encouraging results in improving steatohepatitis and fibrosis in up to 36% and 27% of 29 adult patients, respectively. However, there are currently no ongoing studies evaluating the effect of resmetirom in obese children with MASLD [49].
Despite promising results regarding the administration of resmetirom in adult patients with MASLD/MASH, there is a lack of clinical trials on its long-term safety in these patients. Also, absence of long-term studies on the progression of MASLD in children and adolescents remains an obstacle in developing pharmacotherapeutic approaches to pediatric MASLD. This highlights the need for further research assessing the long-term safety of resmetirom in adult patients, as well as the potential use of resmetirom in treating pediatric MASLD.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Knezović, E.; Hefer, M.; Blažanović, S.; Petrović, A.; Tomičić, V.; Srb, N.; Kirner, D.; Smolić, R.; Smolić, M. Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr. Issues Mol. Biol. 2025, 47, 154. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Knezović, E.; Hefer, M.; Blažanović, S.; Petrović, A.; Tomičić, V.; Srb, N.; Kirner, D.; Smolić, R.; Smolić, M. Correction: Knezović et al. Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr. Issues Mol. Biol. 2025, 47, 154. Curr. Issues Mol. Biol. 2025, 47, 979. https://doi.org/10.3390/cimb47120979

AMA Style

Knezović E, Hefer M, Blažanović S, Petrović A, Tomičić V, Srb N, Kirner D, Smolić R, Smolić M. Correction: Knezović et al. Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr. Issues Mol. Biol. 2025, 47, 154. Current Issues in Molecular Biology. 2025; 47(12):979. https://doi.org/10.3390/cimb47120979

Chicago/Turabian Style

Knezović, Elizabeta, Marija Hefer, Suzana Blažanović, Ana Petrović, Vice Tomičić, Nika Srb, Damir Kirner, Robert Smolić, and Martina Smolić. 2025. "Correction: Knezović et al. Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr. Issues Mol. Biol. 2025, 47, 154" Current Issues in Molecular Biology 47, no. 12: 979. https://doi.org/10.3390/cimb47120979

APA Style

Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025). Correction: Knezović et al. Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr. Issues Mol. Biol. 2025, 47, 154. Current Issues in Molecular Biology, 47(12), 979. https://doi.org/10.3390/cimb47120979

Article Metrics

Back to TopTop